drugset / Trial / NCT03895385

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

NCT03895385

Phase 1 Completed 56 enrolled UCB Biopharma S.P.R.L.
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of the study is to evaluate whether administration of bimekizumab has an effect on the expected production of antibody titers to the influenza vaccine.

Timeline

Start
2019-04-02
Primary completion
2019-10-04
Completion
2019-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimekizumab Monoclonal antibody

Indications

No indication recorded.